

# Pharmacy BULLETIN BOARD

Retail Issue ■ Monday March 10, 2014.

**UriSec® emollient creams and lotions are patient friendly formulations ideal for winter dryness and itchy skin.**

Product	Sizes	Odan Code	Kohl & Frisch Code	McKesson Coe	McMahon Code
UriSec® 10% Cream NPN 80005397	75 g	38075	32617	513085	26638401
	120 g	38045	32618	513341	26638301
UriSec® 12% Lotion NPN 00514896	250 mL	230J	48909	115493	26623101
	120 g	220Q	46312	115444	26623201
UriSec® 22% Cream NPN 00396125	225 g	220C	-	153486	26537801
	454 g	220R	46309	848549	26632301
UriSec® 40 Cream NPN 80005531	15 g	45014	114939	003743	-
	30 g	45028	32606	799437	27127401
	100 g	45067	32616	799494	26640001

UriSec® products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at [info@odanlab.com](mailto:info@odanlab.com). You can also visit our website at [www.odanlab.com](http://www.odanlab.com)



UriSec® is a registered trademark of Odan Laboratories Ltd.

## FROM THE NEWSWIRE

**DORVAL, QC:** Study results presented at the 55<sup>th</sup> American Society of Hematology (ASH) annual meeting showed that patients with myelofibrosis who received treatment with Jakavi® (ruxolitinib) sustained reductions in spleen volume and sustained improvements in quality of life after three years of treatment. These results were demonstrated in analyses from the Phase III COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy) study. These long-term follow up results build on previously established data and reinforce the sustained efficacy and long-term safety profile of Jakavi® in patients with myelofibrosis.



### Important New Product Announcement from Taro!!!

**Pi<sup>r</sup>Taro-Zoledronic Acid Concentrate**  
Zoledronic Acid for Injection 4 mg/5 mL\*  
Must be diluted before use - for I.V. Infusion

Taro Pharmaceuticals is pleased to announce the launch of Taro-Zoledronic Acid Concentrate Injection

- Generic Version of Zometa®<sup>1</sup>
- Lower Price Alternative and High Quality Product
- Bone Metabolism Regulator<sup>2</sup>

Form	Strength	DIN	Size	UPC
Vial (Concentrate, must be diluted before use, for I.V. infusion)	4 mg/ 5mL	02415186	1 Vial (5 mL)	063691073401

For more information, or to place an order for Taro-Zoledronic Acid Concentrate, please contact your Taro Representative, your wholesaler, our Customer Service department 1-800-268-1975 or visit our Website at [www.taro.ca](http://www.taro.ca).

<sup>1</sup> Data on File, Taro Pharmaceuticals Inc.

<sup>2</sup> Taro-Zoledronic Acid Concentrate Product Monograph

® Zometa is a registered trademark, Novartis Pharmaceuticals Canada Inc

\*Incorporated as the monohydrate

TARO is a registered trademark of Taro Pharmaceuticals Inc.

**TORONTO:** Newfoundland joins seven other provinces in providing individuals living with schizophrenia access to INVEGA SUSTENNA® (paliperidone palmitate), a long-acting monthly treatment option. Available through the Newfoundland and Labrador Prescription Drug Program (NLPDP), INVEGA SUSTENNA® is indicated for the treatment of schizophrenia in adults (18 years and older).

**DORVAL, QC:** Novartis announced that Bexsero® (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection. Bexsero® is the first broad-coverage vaccine to help protect against MenB disease. Prior to Bexsero®, vaccines were only available to help protect against meningococcal strains A, C, W and Y.

To include your communication in the next issue, please contact: Health Response

T: 416-863-5403 | F: 416-863-9620 | [hrc@healthresponse.ca](mailto:hrc@healthresponse.ca)

Next Issue: Monday March 24<sup>th</sup>, 2014

Deadline: Thursday March 20<sup>th</sup>, 2014